Revvity Inc. announced impressive Q1 earnings for fiscal year 2026, achieving $711.1 million in revenue and an adjusted EPS of $1.06, surpassing Wall Street expectations. The company forecasts revenue and profit for 2026 will exceed previous estimates despite a recent divestiture of its China immunodiagnostics unit. As Revvity expands its diagnostics offerings and strengthens its position in health sciences, it has also seen its market cap rise to $10.82 billion.
“Revvity Inc. · stock · outperforms competitors · on strong trading day”
“Revvity Inc. · stock · underperforms · Friday when compared to competitors”
“Revvity · beat · fourth-quarter estimates”
“Revvity · forecast · 2026 revenue and profit · above Wall Street expectations”
“Revvity, Inc. · provides · health science solutions, technologies, expertise, and services · complete workflows from discovery to development, and diagnosis to cure”
“Revvity, Inc. · focuses on · translational multi-omics technologies”
“Revvity, Inc. · focuses on · biomarker identification”
“Revvity, Inc. · focuses on · imaging”
“Revvity, Inc. · focuses on · prediction”
“Revvity, Inc. · focuses on · screening”
“Revvity, Inc. · focuses on · detection and diagnosis”
“Revvity, Inc. · focuses on · informatics”
